Efficacy
of the diabetic supplement Gymnemosupium II, a combination of the extracts of
Gymnema sylvestre, Pterocarpus marsupium, Diachrome and Vanadium administered
to patients with Type 2 diabetes.
Original
Materials and Methods
Each
capsule of Gymnemosupium II is a proprietary formulation of Gymnema sylvestre,
75% standardized extract, Pterocarpus marsupium, 5% standardized
extract, Diachrome, a combination of chromium picolinate and biotin, and
vanadium in the form of bis-glycinate oxo vanadium (BVOG).
Each
Type II diabetic will receive a total of 8 capsules of Gymnemosupium II a day
administered in a four dose a day regiment, 2 capsules will be taken
immediately before breakfast, lunch, supper and evening snack. The dose of 8
capsules a day will be maintained by doubling a dose if necessary if an
individual dose is missed.
Trial
will continue for a period of 90 days utilizing a total of 48 Type II diabetic
subjects ranging in age between 30 to 60 years old and currently have a
hemoglobin A1c>8.0.
Subjects
must be free of any type of renal complication and also not be consuming more
than 200mcg of chromium or 1mg of vanadium daily. All participants will give
written informed consent and continue their normal diet, exercise routine and
doses of oral hypoglycemic and insulin. Two weeks prior and throughout the
trial daily morning fasting and supper postprandial blood glucose will be
monitored.
Hemoglobin
A1c will be taken before administration of the Gymnemosupium II and
immediately upon the conclusion of the study. Body weight and blood pressure
will also be monitored in the beginning and at the close of the trial. All
oral hypoglycemic and insulin doses will be recorded as well. Adverse side
effects, if any, will be noted.
First
Data Results
A
total of 18 patients have completed the 90 day study at this time.
For
these 18 patients
Beginning
A1c Average 8.75---- ranging from 9.7 to 7.8
Ending
A1c Average 7.66---- ranging from 8.8 to 6.9
Average
A1c improvement 1.08---- ranging from 2.7 to 0.4
In
addition 2 patients so far, have reported increased Postprandial readings
after product discontinuation due to completion of the study.
We are
awaiting further data and will have a complete report in the near future,
however early data reports indicate that Gym II is a safe and effective
product
